Pernix Therapeutics (PTX) Tops Q4 EPS by 7c
Get Alerts PTX Hot Sheet
Join SI Premium – FREE
Pernix Therapeutics (NASDAQ: PTX) reported Q4 EPS of $0.25, $0.07 better than the analyst estimate of $0.18. Revenue for the quarter came in at $53 million versus the consensus estimate of $52.7 million.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY7,800 at Jefferies, 'emerged stronger since the last earnings season'
- 22nd Century Group (XXII) Reports Q4 Revenue of $7.4M, Net Loss of $22.1M
- NRx Pharmaceuticals (NRXP) Reports Prelim FY23 Results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!